Experienced in Cerebelloparenchymal Disorder 3

Dr. Kevin N. Sheth

Neurology
110 S Paca St, 3rd Floor, Department Of Neurology, 
Baltimore, MD 
Experienced in Cerebelloparenchymal Disorder 3
110 S Paca St, 3rd Floor, Department Of Neurology, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kevin Sheth is a Neurologist in Baltimore, Maryland. Dr. Sheth is rated as an Experienced provider by MediFind in the treatment of Cerebelloparenchymal Disorder 3. His top areas of expertise are Stroke, Subdural Hematoma, Subarachnoid Hemorrhage, Thrombectomy, and Craniectomy.

His clinical research consists of co-authoring 496 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Cerebelloparenchymal Disorder 3.

Specialties
Neurology
Licenses
Psychiatry & Neurology in MD
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

110 S Paca St, 3rd Floor, Department Of Neurology, Baltimore, MD 21201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
Enrollment Status: Terminated
Publish Date: November 25, 2024
Intervention Type: Drug
Study Drug: BIIB093
Study Phase: Phase 3
A Multi-Center, Prospective, Open Label, Phase IIa Trial of RP-1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Experience Clinically Significant Brain Swelling.
A Multi-Center, Prospective, Open Label, Phase IIa Trial of RP-1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Experience Clinically Significant Brain Swelling.
Enrollment Status: Completed
Publish Date: November 22, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized, Multi-Center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
A Randomized, Multi-Center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Enrollment Status: Completed
Publish Date: November 12, 2024
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

496 Total Publications

Association of Component Strategies of the Target Stroke Phase 3 Nationwide Quality Improvement Program With Accelerated Door-to-Puncture and Door-In-Door-Out Times for Ischemic Stroke Endovascular Thrombectomy in the United States.
Association of Component Strategies of the Target Stroke Phase 3 Nationwide Quality Improvement Program With Accelerated Door-to-Puncture and Door-In-Door-Out Times for Ischemic Stroke Endovascular Thrombectomy in the United States.
Journal: Circulation. Cardiovascular quality and outcomes
Published: October 20, 2025
Similar Doctors
Distinguished in Cerebelloparenchymal Disorder 3
Dr. David S. Zee
Neurology
Distinguished in Cerebelloparenchymal Disorder 3
Dr. David S. Zee
Neurology
600 N Wolfe St, 
Baltimore, MD 
 (1.8 miles away)
410-955-9441
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Zee is a Neurologist in Baltimore, Maryland. Dr. Zee is rated as a Distinguished provider by MediFind in the treatment of Cerebelloparenchymal Disorder 3. His top areas of expertise are Vertigo, Brown Syndrome, Cerebelloparenchymal Disorder 3, and Benign Paroxysmal Positional Vertigo. Dr. Zee is currently accepting new patients.

Experienced in Cerebelloparenchymal Disorder 3
Dr. Daniel R. Gold
Neurology | Ophthalmology
Experienced in Cerebelloparenchymal Disorder 3
Dr. Daniel R. Gold
Neurology | Ophthalmology

Johns Hopkins University

600 N Wolfe St, Blalock 266, 
Baltimore, MD 
 (1.8 miles away)
410-502-4340
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Gold is a Neurologist and an Ophthalmologist in Baltimore, Maryland. Dr. Gold is rated as a Distinguished provider by MediFind in the treatment of Cerebelloparenchymal Disorder 3. His top areas of expertise are Vertigo, Benign Paroxysmal Positional Vertigo, Brown Syndrome, and Stiff Person Syndrome. Dr. Gold is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sheth's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 25 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile